Among patients with relapsed/refractory multiple myeloma (RRMM), treatment with belantamab mafodotin appears to be a valid therapeutic option with potential clinical benefits, according to a real-world analysis presented at the 19th Annual Meeting and Exposition of the International Myeloma Society.

Lire la suite ici.